JP2018508183A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508183A5 JP2018508183A5 JP2017534208A JP2017534208A JP2018508183A5 JP 2018508183 A5 JP2018508183 A5 JP 2018508183A5 JP 2017534208 A JP2017534208 A JP 2017534208A JP 2017534208 A JP2017534208 A JP 2017534208A JP 2018508183 A5 JP2018508183 A5 JP 2018508183A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- patient
- postn
- signature genes
- stromal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462096355P | 2014-12-23 | 2014-12-23 | |
| US62/096,355 | 2014-12-23 | ||
| US201562200340P | 2015-08-03 | 2015-08-03 | |
| US62/200,340 | 2015-08-03 | ||
| PCT/US2015/067427 WO2016106340A2 (en) | 2014-12-23 | 2015-12-22 | Compositions and methods for treating and diagnosing chemotherapy-resistant cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018508183A JP2018508183A (ja) | 2018-03-29 |
| JP2018508183A5 true JP2018508183A5 (enExample) | 2019-02-07 |
Family
ID=55275162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017534208A Pending JP2018508183A (ja) | 2014-12-23 | 2015-12-22 | 化学療法耐性癌を治療及び診断する組成物及び方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20170253933A1 (enExample) |
| EP (1) | EP3237639A2 (enExample) |
| JP (1) | JP2018508183A (enExample) |
| KR (1) | KR20170094165A (enExample) |
| CN (1) | CN107109491A (enExample) |
| AU (1) | AU2015369624A1 (enExample) |
| BR (1) | BR112017010788A2 (enExample) |
| CA (1) | CA2968359A1 (enExample) |
| HK (1) | HK1243141A1 (enExample) |
| IL (1) | IL252361A0 (enExample) |
| MX (1) | MX2017006864A (enExample) |
| RU (1) | RU2710735C2 (enExample) |
| SG (1) | SG11201704707PA (enExample) |
| WO (1) | WO2016106340A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3548035A4 (en) | 2016-11-30 | 2020-07-22 | Case Western Reserve University | COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES |
| CN110573154A (zh) | 2017-02-06 | 2019-12-13 | 卡斯西部储备大学 | 调节短链脱氢酶活性的组合物和方法 |
| AU2018368639B2 (en) * | 2017-11-20 | 2025-02-27 | Tolremo Therapeutics Ag | Diagnostic method |
| KR102141997B1 (ko) | 2017-11-22 | 2020-08-06 | (주)인핸스드바이오 | Pmvk를 유효성분으로 포함하는 방사선 저항성 암 진단용 또는 방사선 치료 예후 예측용 바이오마커 조성물 |
| WO2019103456A2 (ko) * | 2017-11-22 | 2019-05-31 | 울산대학교 산학협력단 | Pmvk를 유효성분으로 포함하는 방사선 저항성 암 진단용 또는 방사선 치료 예후 예측용 바이오마커 조성물 |
| TWI841554B (zh) | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法 |
| US11447769B2 (en) | 2018-03-27 | 2022-09-20 | The Trustees Of The University Of Pennsylvania | Modified immune cells having enhanced function and methods for screening for same |
| JP7460608B2 (ja) | 2018-05-07 | 2024-04-02 | ジェンマブ エー／エス | 抗ｐｄ－１抗体と抗組織因子抗体－薬物コンジュゲートとの組み合わせを用いるがんの治療方法 |
| CN112367994A (zh) * | 2018-06-27 | 2021-02-12 | 株式会社麦迪帕克特 | 诊断和治疗表达高水平TGF-β应答标记的癌症患者的方法 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| TWI844571B (zh) * | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| WO2020092808A1 (en) * | 2018-10-31 | 2020-05-07 | Regents Of The University Of Minnesota | Methods for predicting a response to bevacizumab or platinum-based chemotherapy or both in patients with ovarian cancer |
| WO2020106998A1 (en) | 2018-11-21 | 2020-05-28 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
| WO2020140927A1 (en) * | 2019-01-02 | 2020-07-09 | Crownmab Biotech Inc. | Cancer treatment using multi-targeted kinase inhibitor in combination of protein kinase biomarkers |
| CN110563830B (zh) * | 2019-09-16 | 2021-01-29 | 中南大学湘雅医院 | Anxa1衍生多肽及其应用 |
| TW202128174A (zh) * | 2019-10-09 | 2021-08-01 | 美商G1治療公司 | 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療 |
| CN110950960B (zh) * | 2019-11-26 | 2021-05-14 | 中国农业大学 | 基于高通量测序和杂合杂交瘤技术的小分子化合物抗体的制备方法 |
| CA3171333A1 (en) * | 2020-02-20 | 2021-08-26 | Versitech Limited | Pd1-based vaccination composition and methods thereof |
| AU2021224268A1 (en) | 2020-02-21 | 2022-09-15 | Case Western Reserve University | Compositions and methods for treating renal injury |
| CN111440871A (zh) * | 2020-04-26 | 2020-07-24 | 至本医疗科技（上海）有限公司 | 基因标记物在肺癌预后判断中的应用 |
| RU2738167C1 (ru) * | 2020-06-08 | 2020-12-09 | федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии" Министерства здравоохранения Российской Федерации | Способ определения эффективности химиотерапии препаратами платины при раке яичников III-IV стадии |
| EP4302093A1 (en) * | 2021-03-01 | 2024-01-10 | Genentech, Inc. | Diagnostic methods and methods of treatment of ovarian cancer |
| CN114230656B (zh) * | 2021-03-24 | 2025-02-25 | 深圳市新靶向生物科技有限公司 | 一种与食道癌驱动基因突变相关的抗原肽组合及其应用 |
| CN113174439B (zh) * | 2021-03-30 | 2022-06-28 | 中国医学科学院肿瘤医院 | 一种基于免疫基因对评分体系在预测非小细胞肺癌患者免疫治疗效果中的应用 |
| KR20230001587A (ko) * | 2021-06-28 | 2023-01-05 | 연세대학교 산학협력단 | 암의 예방 또는 치료용 약학 조성물 |
| CN113876753A (zh) * | 2021-10-20 | 2022-01-04 | 复旦大学附属中山医院 | 重组人半乳糖凝集素1抑制剂的制药用途 |
| US20260085356A1 (en) * | 2022-09-07 | 2026-03-26 | The Asan Foundation | Biomarker for diagnosing pre-chemotherapy resistance in solid cancer patients and method for providing information for diagnosing pre-chemotherapy resistance, using same |
| CN116434963A (zh) * | 2023-03-02 | 2023-07-14 | 浙江大学 | 超米兰标准的肝细胞癌肝移植受者西罗莫司的疗效预测模型 |
| CN117248022A (zh) * | 2023-10-24 | 2023-12-19 | 郑州大学第一附属医院 | 双硫死亡相关基因及风险模型预测肾上腺皮质癌预后及治疗中的应用 |
| CN119224306A (zh) * | 2024-09-26 | 2024-12-31 | 上海交通大学医学院附属仁济医院 | Gprc5a的新用途 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| DE69025946T2 (de) | 1989-09-08 | 1996-10-17 | Univ Duke | Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma |
| US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| EP0646178A1 (en) | 1992-06-04 | 1995-04-05 | The Regents Of The University Of California | expression cassette with regularoty regions functional in the mammmlian host |
| KR100335584B1 (ko) | 1992-10-28 | 2002-11-29 | 제넨테크, 인코포레이티드 | 혈관내피세포성장인자에대한길항제 |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| ATE207366T1 (de) | 1993-12-24 | 2001-11-15 | Merck Patent Gmbh | Immunokonjugate |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
| KR100441557B1 (ko) | 1994-07-21 | 2005-08-05 | 아크조 노벨 엔.브이. | 고리형케톤과산화물조성물 |
| US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| ATE446955T1 (de) | 1995-03-30 | 2009-11-15 | Pfizer Prod Inc | Chinazolinone derivate |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| CA2222231A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
| PL188959B1 (pl) | 1995-07-06 | 2005-05-31 | Novartis Ag | Pirolopirymidyny i sposoby ich wytwarzania |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| CN100503580C (zh) | 1996-04-12 | 2009-06-24 | 沃尼尔·朗伯公司 | 酪氨酸激酶的不可逆抑制剂 |
| US6391874B1 (en) | 1996-07-13 | 2002-05-21 | Smithkline Beecham Corporation | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| DE69829891T2 (de) | 1997-04-07 | 2005-10-06 | Genentech, Inc., South San Francisco | Anti-VEGF Antikörper |
| CN104231078A (zh) | 1997-04-07 | 2014-12-24 | 基因技术股份有限公司 | 抗-血管内皮生长因子的抗体 |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| AU7165698A (en) | 1997-05-06 | 1998-11-27 | American Cyanamid Company | Use of quinazoline compounds for the treatment of polycystic kidney disease |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| AU1308799A (en) | 1997-11-06 | 1999-05-31 | American Cyanamid Company | Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps |
| CN1160338C (zh) | 1998-11-19 | 2004-08-04 | 沃尼尔·朗伯公司 | N-[4-(3-氯-4-氟-苯基氨基)-7-(3-吗啉-4-基-丙氧基)-喹唑啉-6-基]-丙烯酰胺,不可逆的酪氨酸激酶抑制剂 |
| US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| AU2003221684A1 (en) | 2002-04-08 | 2003-10-27 | Smithkline Beecham Corporation | Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor |
| RS20150135A1 (sr) | 2003-05-30 | 2015-08-31 | Genentech Inc. | Tretman sa anti-vegf antitelima |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| US20060009360A1 (en) | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
| WO2008098086A2 (en) * | 2007-02-06 | 2008-08-14 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | A gene expression profile that predicts ovarian cancer subject response to chemotherapy |
| WO2009074968A2 (en) * | 2007-12-12 | 2009-06-18 | Ecole Polytechnique Federale De Lausanne (Epfl) | Method for predicting the efficacy of cancer therapy |
| WO2011153345A2 (en) * | 2010-06-03 | 2011-12-08 | Beth Israel Deaconess Medical Center, Inc. | A gene expression profile of brca-ness that correlates with responsiveness to chemotherapy and with outcome in cancer patients |
| KR101615420B1 (ko) | 2010-12-16 | 2016-04-26 | 제넨테크, 인크. | Th2 억제에 관한 진단 및 치료 |
| MX2014011582A (es) * | 2012-03-30 | 2014-11-21 | Genentech Inc | Metodos y composiciones de diagnostico para el tratamiento de cancer. |
| WO2013180274A1 (ja) * | 2012-06-01 | 2013-12-05 | 大鵬薬品工業株式会社 | 胃癌患者に対する化学療法の選択方法 |
| CA2886607A1 (en) * | 2012-10-17 | 2014-04-24 | Cedars-Sinai Medical Center | Molecular signatures of ovarian cancer |
| HK1214633A1 (zh) * | 2012-12-03 | 2016-07-29 | Almac Diagnostics Limited | 癌症的分子诊断测试 |
-
2015
- 2015-12-22 EP EP15831106.8A patent/EP3237639A2/en not_active Withdrawn
- 2015-12-22 CN CN201580070095.7A patent/CN107109491A/zh active Pending
- 2015-12-22 CA CA2968359A patent/CA2968359A1/en not_active Abandoned
- 2015-12-22 RU RU2017125054A patent/RU2710735C2/ru active
- 2015-12-22 BR BR112017010788A patent/BR112017010788A2/pt not_active Application Discontinuation
- 2015-12-22 HK HK18102602.6A patent/HK1243141A1/zh unknown
- 2015-12-22 WO PCT/US2015/067427 patent/WO2016106340A2/en not_active Ceased
- 2015-12-22 AU AU2015369624A patent/AU2015369624A1/en not_active Abandoned
- 2015-12-22 KR KR1020177014690A patent/KR20170094165A/ko not_active Withdrawn
- 2015-12-22 SG SG11201704707PA patent/SG11201704707PA/en unknown
- 2015-12-22 JP JP2017534208A patent/JP2018508183A/ja active Pending
- 2015-12-22 MX MX2017006864A patent/MX2017006864A/es unknown
-
2017
- 2017-05-17 US US15/597,789 patent/US20170253933A1/en not_active Abandoned
- 2017-05-18 IL IL252361A patent/IL252361A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017125054A (ru) | Композиции и способы лечения и диагностики резистентного к химиотерапии рака | |
| Singh et al. | TNBC: potential targeting of multiple receptors for a therapeutic breakthrough, nanomedicine, and immunotherapy | |
| Huyghe et al. | Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours? | |
| Røsland et al. | Novel points of attack for targeted cancer therapy | |
| Liu et al. | The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4 | |
| Lote et al. | PD-1 and PD-L1 blockade in gastrointestinal malignancies | |
| Basu et al. | Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer | |
| Gilbert et al. | A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma | |
| Kim et al. | Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study | |
| Petrillo et al. | Biomarkers for precision treatment in gastric cancer | |
| Alsaafeen et al. | Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors | |
| JP2019510785A (ja) | 癌を処置する方法 | |
| Ishii et al. | Dawn of precision medicine on gastric cancer | |
| JP2017535548A5 (enExample) | ||
| Gui et al. | Tislelizumab plus nab-paclitaxel and cisplatin as induction immunochemotherapy for organ preservation of locally advanced hypopharyngeal squamous cell carcinoma: a single-arm phase II trial | |
| Yao et al. | It’s high-time to re-evaluate the value of induced-chemotherapy for reinforcing immunotherapy in colorectal cancer | |
| Duenas-Gonzalez et al. | Emerging drugs for cervical cancer | |
| Li et al. | Preoperative pembrolizumab (anti-PD-1 antibody) combined with chemoradiotherapy for esophageal squamous cell carcinoma: a phase 1/2 trial (PALACE-2) | |
| RU2017120388A (ru) | Прогнозирование ответа на антагонист vegf | |
| Hall et al. | Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials | |
| Qi et al. | The co-inhibitory immune checkpoint proteins B7-H1 (PD-L1) and B7-H4 in high grade glioma: from bench to bedside | |
| Gui et al. | Efficacy, safety, and multi-omics analysis of pembrolizumab combined with nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: A single-arm phase 2 study | |
| Wairagu et al. | Combined therapeutic potential of nuclear receptors with receptor tyrosine kinase inhibitors in lung cancer | |
| Kenneth | Advances in systemic therapy in pancreatic cancer | |
| US20220313724A1 (en) | Compositions for intratumoral administration and related methods |